. 2024 Mar 14;42(14):1687–1698. doi: 10.1200/JCO.23.02105

TABLE A2.

rPFS and OS by Each Single HRR Gene Mutation (without comutation with the other five genes)

Gene Mutation	End Point	Arm	No.	No. of Events	Median Survival, Months	HR^a (95% CI)	HR^b (95% CI)
ATMm	rPFS BICR	PARP + ARPI	111	52	19 (17-NE)	0.96 (0.65 to 1.42)	0.93 (0.62 to 1.39)
	rPFS BICR	Placebo + ARPI	112	49	19 (14-NE)	0.96 (0.65 to 1.42)	0.93 (0.62 to 1.39)
	OS	PARP + ARPI	111	46	37 (29-NE)	0.95 (0.63 to 1.43)	0.89 (0.59 to 1.36)
	OS	Placebo + ARPI	112	48	33 (28-NE)	0.95 (0.63 to 1.43)	0.89 (0.59 to 1.36)
BRCA1m	rPFS BICR	PARP + ARPI	28	9	NE (16-NE)	0.44 (0.17 to 1.12)	0.23 (0.06 to 0.91)
	rPFS BICR	Placebo + ARPI	18	10	12 (4-NE)	0.44 (0.17 to 1.12)	0.23 (0.06 to 0.91)
	OS	PARP + ARPI	28	10	NE (24-NE)	0.63 (0.24 to 1.68)	0.46 (0.12 to 1.69)
	OS	Placebo + ARPI	18	8	26 (15-NE)	0.63 (0.24 to 1.68)	0.46 (0.12 to 1.69)
BRCA2m	rPFS BICR	PARP + ARPI	178	54	NE (22-NE)	0.29 (0.21 to 0.4)	0.26 (0.18 to 0.36)
	rPFS BICR	Placebo + ARPI	183	121	10 (8-11)	0.29 (0.21 to 0.4)	0.26 (0.18 to 0.36)
	OS	PARP + ARPI	178	69	33 (28-NE)	0.66 (0.48 to 0.9)	0.63 (0.46 to 0.88)
	OS	Placebo + ARPI	183	96	24 (21-28)	0.66 (0.48 to 0.9)	0.63 (0.46 to 0.88)
CDK12m	rPFS BICR	PARP + ARPI	55	24	22 (16-NE)	0.53 (0.31 to 0.89)	0.54 (0.31 to 0.93)
	rPFS BICR	Placebo + ARPI	61	33	16 (11-19)	0.53 (0.31 to 0.89)	0.54 (0.31 to 0.93)
	OS	PARP + ARPI	55	20	NE (29-NE)	0.47 (0.27 to 0.83)	0.49 (0.28 to 0.88)
	OS	Placebo + ARPI	61	36	29 (20-34)	0.47 (0.27 to 0.83)	0.49 (0.28 to 0.88)
CHEK2m	rPFS BICR	PARP + ARPI	58	21	NE (14-NE)	0.84 (0.47 to 1.5)	0.8 (0.44 to 1.44)
	rPFS BICR	Placebo + ARPI	64	31	18 (11-NE)	0.84 (0.47 to 1.5)	0.8 (0.44 to 1.44)
	OS	PARP + ARPI	58	21	NE (25-NE)	0.97 (0.54 to 1.74)	0.96 (0.53 to 1.75)
	OS	Placebo + ARPI	64	26	34 (24-NE)	0.97 (0.54 to 1.74)	0.96 (0.53 to 1.75)
PALB2m	rPFS BICR	PARP + ARPI	19	10	29 (8-NE)	0.41 (0.16 to 1.04)	0.27 (0.07 to 0.98)
	rPFS BICR	Placebo + ARPI	13	10	11 (2-14)	0.41 (0.16 to 1.04)	0.27 (0.07 to 0.98)
	OS	PARP + ARPI	19	9	29 (15-NE)	0.63 (0.24 to 1.65)	0.49 (0.14 to 1.73)
	OS	Placebo + ARPI	13	9	20 (11-38)	0.63 (0.24 to 1.65)	0.49 (0.14 to 1.73)

Abbreviations: ARPI, androgen receptor pathway inhibitor; BICR, blinded independent central review; HR, hazard ratio; HRR, homologous recombination repair; NE, not estimable; OS, overall survival; PARP, poly(ADP-ribose) polymerase; rPFS, radiographic progression-free survival.

^{^a}

HR estimated from a Cox proportional hazards model stratified by trial (HR <1 favors the treatment group).

^{^b}

HR estimated from a Cox proportional hazards model stratified by trial and adjusted by baseline Eastern Cooperative Oncology Group performance status, metastasis site (bone only v visceral disease v others) and Gleason score (≤7 v >7; HR < 1 favors the PARPi group).